The pharmaceutical community is buzzing about Retatrutide 120 , a twin-action therapy showing remarkable benefits in early studies . This innovative compound, a glucagon-like peptide-1 receptor agonist alongside a similar molecule , appears to substantially decrease body mass and positively affec